作者
Tim Crul,N. Tóth,Stefano Piotto,Peter Literati-Nagy,Kálmán Tory,Pierre Haldimann,Bernadett Kalmár,Linda Greensmith,Zsolt Török,Gábor Balogh,Imre Gombos,Federica Campana,Simona Concilio,Ferenc Gallyas,Gábor Nagy,Zoltán Berente,Burçin Güngör,Mária Péter,Attila Glatz,Ákos Hunya,Zsuzsanna Literáti-Nagy,László Vı́gh,Femke Hoogstra‐Berends,André Heeres,Irma Kuipers,Lizette Loen,Jean-Paul Seerden,Deli Zhang,Roelien A. M. Meijering,Robert H. Henning,Bianca J.J.M. Brundel,Harm H. Kampinga,László Korányi,Zoltán Szilvássy,József Mandl,Balázs Sümegi,Mark A. Febbraio,Ibolya Horváth,Philip L. Hooper,László Vı́gh
摘要
According to the "membrane sensor" hypothesis, the membrane's physical properties and microdomain organization play an initiating role in the heat shock response. Clinical conditions such as cancer, diabetes and neurodegenerative diseases are all coupled with specific changes in the physical state and lipid composition of cellular membranes and characterized by altered heat shock protein levels in cells suggesting that these "membrane defects" can cause suboptimal hsp-gene expression. Such observations provide a new rationale for the introduction of novel, heat shock protein modulating drug candidates. Intercalating compounds can be used to alter membrane properties and by doing so normalize dysregulated expression of heat shock proteins, resulting in a beneficial therapeutic effect for reversing the pathological impact of disease. The membrane (and lipid) interacting hydroximic acid (HA) derivatives discussed in this review physiologically restore the heat shock protein stress response, creating a new class of "membrane-lipid therapy" pharmaceuticals. The diseases that HA derivatives potentially target are diverse and include, among others, insulin resistance and diabetes, neuropathy, atrial fibrillation, and amyotrophic lateral sclerosis. At a molecular level HA derivatives are broad spectrum, multi-target compounds as they fluidize yet stabilize membranes and remodel their lipid rafts while otherwise acting as PARP inhibitors. The HA derivatives have the potential to ameliorate disparate conditions, whether of acute or chronic nature. Many of these diseases presently are either untreatable or inadequately treated with currently available pharmaceuticals. Ultimately, the HA derivatives promise to play a major role in future pharmacotherapy.